NHS: A High Yield Without a Moat

For the value investor, a high yield is a siren song. It promises a return on capital, a tangible reward for patience. But when that yield is disconnected from the underlying earnings, it signals a classic trap. The case of Neuberger Berman High Yield Strategies Fund (NHS) is a textbook example of this tension. The fund offers a trailing dividend yield of 14.41%, based on an annual payout of $1.09. That figure is eye-catching, especially for a closed-end fund focused on high-yield debt. Yet it stands in stark contrast to the financial reality of the business.

The problem is the precipitous drop in earnings. For the year 2025, the fund's earnings fell by 46.72% to just $20.22 million. In other words, the income stream supporting that massive yield has been cut nearly in half. This creates an immediate dilemma: how can a distribution of $0.0905 per month be sustained when the profits that should cover it are collapsing?

The mechanism for this disconnect is laid bare in the fund's own disclosures. Under its level distribution policy, the monthly payment of $0.0905 may consist of net investment income, net realized capital gains and return of capital. This is the critical admission. When a fund pays a distribution that exceeds its net investment income, it is effectively returning a portion of the investor's principal. Over time, this erodes the capital base of the investment, turning a high yield into a slow drawdown of the original stake. The fund's ability to maintain this rate is not guaranteed and depends on a mix of income, leverage costs, and other expenses.

The bottom line is a conflict between appearance and substance. The 14.4% yield looks like a bargain, a rich return for taking on risk. But the 47% earnings collapse shows the business is under severe pressure. For a disciplined investor, the true measure of a company's health is not its dividend yield, but its ability to generate earnings that can sustain it. NHS's yield is not supported by its earnings; it is supported by a policy that may be siphoning off capital. This is the essence of the value trap: a tempting return that comes at the cost of the principal itself.

The Engine of the Yield: Leverage and Concentration

The fund's ability to maintain its $0.0905 monthly distribution is a precarious balancing act. Its sustainability hinges on a narrow set of factors: the income generated from its portfolio, the cost of the leverage it employs, and the level of its operating expenses. As the fund's own statement notes, its capacity to pay this amount depends on the amount and stability of income received from its investments, the cost of leverage and the level of other Fund fees and expenses. This creates a direct vulnerability. When the income stream weakens-as it has with a 46.72% drop in earnings-the pressure on the distribution intensifies, making the role of leverage and expense management even more critical.

This is where the closed-end fund structure amplifies the risk. Leverage is a double-edged sword. It magnifies gains when the fund's investments perform well, but it also magnifies losses when they falter. For a fund like NHS, which invests in high-yield debt, the cost of this borrowed capital can swing dramatically with interest rates and market sentiment. In a rising rate environment, the expense of leverage can quickly consume a larger portion of the fund's net investment income, squeezing the margin available to cover the distribution. This structural feature turns a modest decline in portfolio income into a more severe hit to the distribution's funding.

The portfolio's concentration further compounds this fragility. NHS is a pure-play on high-yield debt, with holdings across sectors like auto parts and equipment, airlines, automotive, electronics, health services, packaging, telecom-integrated/services, gaming, and gas distribution. This creates a portfolio that is acutely sensitive to credit cycles and sector-specific downturns. A recession or a sector-specific crisis can trigger a wave of defaults or downgrades, collapsing the income stream from these very securities. The fund's income is not diversified across a broad range of stable, investment-grade assets; it is concentrated in a riskier, more volatile segment of the market.

The bottom line is a fragile income engine. The distribution is funded by a mix of potentially unstable income, the cost of borrowed money, and operating expenses. The fund's leverage multiplies the impact of any misstep, while its concentrated portfolio exposes it to significant credit risk. This setup means the high yield is not a product of a wide, durable moat, but of a leveraged bet on a volatile asset class. For a value investor, that is a recipe for volatility and potential capital erosion, not a sustainable compounding machine.

Valuation and the Margin of Safety

The market price of Neuberger Berman High Yield Strategies Fund (NHS) reflects a clear appeal to a specific investor: those seeking maximum current income. With a market capitalization of approximately $234 million, the fund is a niche vehicle that has proven popular with investors interested in earning a very high level of current income . This popularity is what supports its price and its massive trailing yield of 14.41%. Yet for the value investor, this very popularity is a red flag. It signals a market that is focusing on the headline yield while overlooking the fundamental disconnect between that yield and the business's deteriorating earnings.

The classic warning sign is the 47% collapse in annual earnings to just $20.22 million. When a distribution is paid from a source that is shrinking, the margin of safety evaporates. The fund's own policy acknowledges this risk, stating that the $0.0905 monthly distribution may consist of net investment income, net realized capital gains and return of capital. This is the value trap in plain language. A high yield supported by a return of capital is not a sustainable return on investment; it is a return of the investment itself.

The primary risk is that the distribution will need to be reduced if earnings do not recover. The fund's ability to maintain this rate depends on a precarious mix of income, leverage costs, and expenses . With earnings already cut nearly in half, the margin for error is thin. Any further deterioration in portfolio income would force a difficult choice: either cut the distribution, which would likely trigger a share price decline as the high yield is no longer supported, or continue the current payout by drawing down capital, which erodes the principal. Either path threatens the capital base.

From a value perspective, the current price offers no margin of safety. The intrinsic value of the fund is tied to the sustainability of its earnings and its ability to fund the distribution without capital erosion. The market is pricing NHS as if the 14.4% yield is a permanent feature, but the evidence shows it is a temporary artifact of a stressed business. For a disciplined investor, the lesson is clear: a high yield is not a margin of safety. It is often the most expensive signal of a value trap, where the price of admission is paid in the form of a shrinking capital base.

Catalysts and Watchpoints

For an investor navigating the NHS value trap, the path forward is defined by a few clear, near-term events. The fund's high yield is a promise, but its sustainability depends entirely on the outcome of these upcoming milestones. Here is the actionable watchlist.

First, the quarterly earnings reports are the most direct measure of the business's health. The fund's 46.72% drop in earnings to $20.22 million last year was a severe warning. The next set of financial results will show whether that decline is stabilizing or accelerating. Any further deterioration in net investment income would directly threaten the fund's ability to fund its $0.0905 monthly distribution without drawing down capital. This is the primary financial metric to monitor.

Second, and most critical, is any announcement regarding the distribution itself. The fund's policy explicitly states it is subject to market conditions, unless further action is taken to determine another amount. The market's focus will be on whether the board maintains the status quo or signals a cut. A reduction would be a definitive admission that the current yield is not sustainable, likely triggering a sharp share price decline as the high yield is no longer supported. Investors should watch for any formal notice of a change in distribution amount.

Third, the performance of the underlying portfolio and the cost of leverage must be assessed. The fund's income is derived from its high yield debt securities, which are sensitive to credit cycles and defaults. Any signs of increasing defaults or downgrades in its concentrated portfolio would erode the income stream. At the same time, the cost of the fund's leverage is a key expense that can swing with interest rates. A widening gap between portfolio income and leverage costs would squeeze the margin available for the distribution. Monitoring portfolio quality reports and interest rate trends is essential.

The bottom line is that the high yield is a temporary anomaly, not a permanent feature. The catalysts are clear: watch the earnings for stabilization, watch for any distribution change, and watch the portfolio and leverage for signs of stress. For a disciplined investor, these are the facts that will determine whether the yield is a sustainable return or a slow erosion of capital.